To calculate breast cancer detection to expected incidence ratios and standardised detection ratios (SDRs) for the New Zealand breast cancer screening programme.
INTRODUCTION
T he New Zealand breast cancer screening programme was established in December 1998. All asymptomatic women aged 50-64 in New Zealand are eligible for screening and are offered two-yearly two-view mammographic screening in the programme. Screening in the New Zealand programme is delivered regionally by six providers. Before the establishment of the national programme, two pilot programmes had been set up in 1991, in Otago and Southland, and in Waikato, to examine the acceptability, effectiveness and economic ef ciency of breast cancer screening in New Zealand. 1 Performance indicators have been developed for the New Zealand breast cancer screening programme, as for screening programmes elsewhere. 2 Two performance indicators that have been developed for the assessment of breast cancer screening programmes are the ratio of the invasive breast cancer detection rate to the expected incidence of invasive breast cancer in the absence of screening, and the standardised detection ratio (SDR). 3 These performance indicators allow the programme to be compared with the results of the Swedish Two-County trial, 4,5 a randomised controlled trial that showed a statistically signi cant reduction in breast cancer mortality associated with invitation to screening. The assumption is that a screening programme that replicates the early characteristics of the Swedish Two-County trial can be expected to effect similar reductions in breast cancer mortality later. The SDR compares actual breast cancer detection in a screening programme with that expected if the programme replicated the performance of the Swedish Two-County Trial, expressed as the ratio of observed to expected cancers detected. 3 If a screening programme's breast cancer detection to expected incidence ratio is 3.0 or greater (in the prevalence screening round), and the SDR is 1.0 or greater, this suggests that the programme is performing as well as or better than the Swedish Two-County trial with respect to breast cancer detection. 3 The results from prevalence screening in the New Zealand programme in 1999 and 2000 for these two performance indicators are reported. For four of the six regional providers of screening, the results included all women screened in 1999 and 2000. In the remaining two regions (i.e. those regions where pilot screening programmes had been operating), only a small proportion of women screened was included, since the majority of women in these two regions received incidence screening in 1999 and 2000 rather than prevalence screening.
METHODS
Cancer registrations for New Zealand for 1976-1999 were obtained from the New Zealand Cancer Registry. Cancer registrations in New Zealand were thought to be almost complete from 1976 to 1985, and 90-95% complete from 1985. 6 Following the introduction of the New Zealand Cancer Registry Act 1993, which came into effect in July 1994 and made cancer registration mandatory, there was a 16% increase in breast cancer registrations between 1993 and 1996, which may partly be due to more complete reporting. 7 The le obtained from the Cancer Registry included the age ( ve-year age group) and domicile code for each woman diagnosed with invasive breast cancer from 1976-1999, together with the year of diagnosis. This information was used to project the expected incidence of invasive breast cancer in New Zealand women aged 50-64 during 1999 and 2000 in the absence of a screening programme.
Two pilot programmes started in New Zealand in 1991, in Otago and Southland, and in Waikato, and this had to be taken into account in the projections, as described below. The New Zealand breast cancer screening programme began in December 1998.
Projected incidence, in the absence of screening, was obtained via a log-linear Poisson regression model in which the log of expected breast cancer incidence was modelled as a function of calendar year, age group and region, as well as indicator variables for the presence of a screening programme. An additional indicator variable was introduced to distinguish prevalence screening from subsequent screening rounds, although this was relevant only for the pilot areas. The model allowed for region-speci c incidence trends and for regional variation in the impact of screening on registrations. However, as a simpli cation, the model assumed that, within regions, time trends (on a log scale) did not vary with age group and that the relative impact of screening did not vary with age group. Projected expected cancer registrations for a given year, in the absence of a screening programme, were obtained from the tted model equation by setting all screening indicator variables to zero.
Letting Y ijk denote the number of cancer registrations in region i, and year j, for age group k, the full model can be written as follows: 
REGINC
=0; S ij =1 if region i was exposed to prevalence screening in year j, otherwise S ij = 0; I ij = 1 if region i was exposed to incidence screening in year j, otherwise I ij = 0.
A Bayesian approach, implemented via Monte Carlo methods, was adopted to assess the uncertainty in model projections and the consequent uncertainty in SDR calculations. In Bayesian analyses, all inferences concerning unknown quantities of interest follow from the conditional probability distribution of the unknown quantity, given the observed data. This conditional distribution is usually referred to as the posterior distribution. The posterior distribution for the Poisson regression model parameters was approximated via a Metropolis algorithm, 8 which, after convergence, generates a random sample of values from the posterior distribution. A uniform prior distribution was adopted so that the posterior distribution was based entirely on the likelihood function for the model. For each setting of the model parameters generated by the Metropolis algorithm, projected registration counts in the absence of screening were obtained by generating from the Poisson distribution, with mean given by the model equation with all screening indicator variables set to zero. The corresponding SDR values were computed from the generated predicted registration counts, observed cancers and assumed prevalence to incidence ratios, as described below. In this way, a random sample from the posterior distribution of the SDR indices was obtained.
In addition to standard study summaries, such as point estimates and uncertainty intervals, this approach permits computation of posterior probabilities of interest, such as the probability the SDR for a given programme exceeds one or some other target value. Unless otherwise stated, point estimates for projected registrations and SDR indices are posterior means and 95% intervals are the intervals de ned by the 2.5th and 97.5th percentiles of the Monte Carlo approximation obtained for the posterior distribution of interest.
The actual number of women who underwent prevalence screening and the number diagnosed with breast cancer in the screening programme in 1999 and 2000 were obtained from the screening programme database. The number of women screened in each region was compared with the number of women aged 50-64 in that region, to calculate the percentage of women aged 50-64 screened. The percentage of women screened was multiplied by the expected number of cancers in the absence of screening, to obtain the number of breast cancers expected among the screened women, in the absence of screening.
The cancer detection performance indicator, the detection to expected incidence ratio, was calculated by dividing the actual number of screened women diagnosed with invasive breast cancer by the number of diagnoses expected among these women in the absence of screening. The target of three times the expected incidence in the absence of screening is derived from comparisons between cancer detection rates in the intervention group and the control group during prevalence screening in a randomised controlled trial of screening. 9 This is also one of the agreed performance indicators for European breast cancer screening programmes. 2 Standard methods were used to calculate the SDRs. 3 The observed number of breast cancers was obtained from the screening programme database. Expected cancers were calculated using the projected incidence of breast cancer among the screened women, multiplied by the prevalence to incidence (P/I) ratios for the prevalence screening round in the Swedish Two-County trial. 3 
RESULTS
In the 1999-2000 time period there were 282,147 women aged 50-64 in New Zealand. women aged 50-64 in each region, and the number undergoing prevalence screening in this period, by ve-year age group. Regions 2 and 6 are the regions where pilot programmes had been established in 1991, so a smaller proportion of eligible women (especially those aged over 55) underwent prevalence screening in these regions than in the other regions. Table 2 shows invasive breast cancer detection results for 1999 and 2000 by region and for the New Zealand programme overall. For prevalence screening in 1999, the programme achieved a breast cancer detection rate of 5.6 per 1000 women screened. This was 2.4 times the incidence of breast cancer expected among these women in the absence of screening. For prevalence screening in 2000, the programme achieved a breast cancer detection rate of 6.0 per 1000 women screened. This was 2.5 times the incidence of breast cancer expected among these women in the absence of screening. Table 3 shows SDRs for prevalence screening in 1999 and 2000 by region. In 1999, the estimated SDR for prevalence screening in the New Zealand breast cancer screening programme was 0.84 (95% interval 0.76-0.94). The posterior probability that the SDR exceeded 1.0 was negligible. On the other hand, the posterior probability that the SDR exceeded 0.75 was approximately 99%. In 2000, the estimated SDR for prevalence screening in the programme was 0.90 (95% interval 0.81-0.99). The posterior probability that the SDR exceeded 1.0 was 1.4% whereas the posterior probability that the SDR exceeded 0.75 was greater than 99.9%. These results strongly suggest that invasive breast cancer detection in the New Zealand programme in the 1999-2000 time period was lower than that observed in the Swedish Two-County trial. However, the New Zealand programme's cancer detection performance appears to be at least 75% that of the Swedish Two-County trial.
For four of the six programmes, posterior probabilities for the SDRs exceeding 0.75 in 2000 were at least 98% and for region 4 there was strong evidence that the SDR exceeded 1.0 (posterior probability equal to 95%). It also seems likely that the SDR for region 6 exceeded 1.0, although the evidence is weaker than for region 4. Region 6 was one of the pilot areas, and the number of women participating in prevalence screening was consequently low.
With one exception, SDRs in all regions appeared to improve in the second year of the programme ( Table 4 ). The posterior probabilities for an increase in SDR between 1999 and 2000 were greater than 0.75 for all regions, except region 2, where the probability of an increase was <0.001.
In order to investigate the potential sensitivity of our results to the speci cation of the model, we recalculated the SDR statistics using a recent set of national projections prepared by the New Zealand Ministry of Health. 10 These projections were obtained as the average of projections from a variety of models but did not allow for the impact of screening in the pilot screening areas. Consequently, the Ministry of Health projections can be expected to overstate projected breast cancer incidence with a corresponding understatement of SDRs. Using the Ministry of Health projections we found SDRs of 0.73 for 1999, and 0.81 for 2000.
DISCUSSION
The New Zealand breast cancer screening programme achieved lower than expected invasive breast cancer detection results in the prevalence screening round, compared with the Swedish Two-County trial. Similarly, the * Expected rate in the absence of screening, estimated by the mean of the posterior distribution of the incidence rate in the absence of screening. † 95% interval for the expected incidence rate in the absence of screening. NZ, New Zealand early results of the NHSBSP showed lower than expected invasive breast cancer detection results compared with the Swedish Two-County trial. The NHSBSP was established from 1988-1993, and has reported SDRs greater than 1.0 since the 1996-1997 time period, suggesting that the NHSBSP has been screening more effectively than the Swedish Two-County trial since the 1996-1997 time period. 11 Thus, both programmes appear to have screened less effectively than the initial years of the Swedish Two-County trial. It may be that it takes some time before new programmes are able to mirror the performance of the Swedish trial. Although the New Zealand programme and the NHSBSP appear to be similar in this respect, there are differences between the NHSBSP and the New Zealand screening programme. Screening is offered two-yearly in New Zealand rather than three-yearly as in the UK, and two-view mammography is used routinely in the New Zealand programme while single-view mammography was initially used in most centres in the NHSBSP. The shorter screening interval would not have an impact on cancers detected at prevalence screening, but the routine use of twoview mammography may increase cancer detection. As in other programmes where SDRs have been calculated, our calculations have not taken into account the likelihood that there is self-selection of high-risk (or low-risk) women for screening. 12 It has been shown that self-selection occurred in some of the randomised controlled trials, and also that there was self-selection of high-risk women for screening in the NHSBSP. 13 Self-selection could affect invasive breast cancer detection rates and SDRs, particularly with lower coverage than that achieved in the Swedish Two-County trial.
Unfortunately, adjustments for self-selection cannot be made for the New Zealand breast cancer screening programme; there is no population register of women eligible for screening in New Zealand, and considerations of privacy have meant that no data are recorded about women who have declined an offer of screening. The absence of these data meant that we were unable to compare breast cancer incidence in women who declined the offer of screening with the expected incidence in the absence of screening, in order to assess self-selection among women who participated in the New Zealand programme.
A further limitation of our results is that some mammography screening in New Zealand occurs in the private sector, outside the New Zealand screening programme. It is possible that some women whose results were included in the prevalence screening data had actually had previous mammograms before their entry into the national screening programme. It is not possible for us to identify such women from routinely collected screening data. If a substantial proportion of the women who underwent rst screens in the New Zealand programme had previously been screened elsewhere, results from these women, such as invasive cancer detection rates, would be similar to incidence screening results rather than prevalence screening results. This could cause invasive breast cancer detection rates and SDRs for prevalence screening in the New Zealand programme to be lower than expected compared with the Swedish Two-County trial, where little mammography screening took place outside of the trial. Although the Bayesian methods described above allow for uncertainty in the model parameters and in projections from the model, it should be noted that they do not re ect uncertainty concerning the form of the model itself. A variety of approaches has been proposed for modelling and forecasting cancer-incidence data, with age-period-cohort models receiving particular attention, fundamental identi ability issues notwithstanding. [14] [15] [16] [17] [18] We adopted a simpler modelling approach, and the model employed in this paper corresponds to an age-period model with period effects modelled via an underlying log-linear trend, together with an additional screening effect for years in which screening programmes were operational. However, the model employed here did not explicitly incorporate cohort effects. We also tted a model with a linear trend for period effects; however, the t of this model was poor compared with the log-linear model. The difference in log-likelihoods was 16.9 in favour of the log-linear model, which represents strong evidence in favour of the log-linear model. 19 Consequently, the log-linear model was preferred.
It is important to monitor cancer detection rates and SDRs in breast cancer screening programmes. It is very encouraging that SDRs for ve of the six regions in the New Zealand programme increased from 1999 to 2000. Possible reasons for the decline in SDR in region 2 need to be investigated. It is possible that there was no improvement in region 2 from 1999 to 2000 because this region already had considerable experience in screening, and thus there was no further learning gain. It is also possible that a poor SDR in a single year (such as 2000) could be owing to random uctuation. Breast cancer detection rates and SDRs for the 2001-2002 time period for the New Zealand national breast cancer screening programme need to be monitored, to see whether there is continuing improvement in cancer detection overall.
